Complications after minor salivary gland biopsy: a retrospective study of 630 patients from two Swedish centres

Scand J Rheumatol. 2023 Mar;52(2):208-216. doi: 10.1080/03009742.2021.1999671. Epub 2022 Jan 20.

Abstract

Objectives: The aims of the study were to investigate the prevalence of impaired sensation after minor salivary gland biopsy (MSGB) in two Swedish centres [Karolinska University Hospital (KUH) and Skåne University Hospital (SUH)] and to assess its impact on quality of life (QoL) and associated risk factors.

Method: A questionnaire including questions regarding the presence of impaired sensation, impact on QoL, and impact on everyday life was sent to patients who had undergone MSGB between 2007 and 2016, and their medical notes were scrutinized.

Results: The study included 630 patients (505 from KUH and 125 from SUH). In KUH the biopsies were performed by rheumatologists and in SUH by dentists or oral and maxillofacial surgeons (OMSs). Long-standing, probably permanent, impaired sensation after MSGB was reported by 21% of patients, and was associated with lower age and absence of anti-SSA antibodies. Patients with long-standing impaired sensation reported the inconvenience (1-10) of impaired sensation as 4.0 (2.0-7.0) [median (interquartile range)], and 32% reported an influence on their QoL, the reported influence (1-10) on everyday life being 3.0 (1.0-5.0). When comparing the outcomes from KUH and SUH, patients from SUH reported a significantly lower frequency of long-standing impaired sensation (14% vs 23%; p = 0.02).

Conclusion: A high frequency of long-standing impaired sensation after MSGB was found among patients who had undergone MSGB, although it had a low impact on everyday life. The complication frequency was less pronounced when a dentist or an OMS had performed the biopsy.

MeSH terms

  • Biopsy / adverse effects
  • Humans
  • Hypesthesia / pathology
  • Quality of Life
  • Retrospective Studies
  • Salivary Glands, Minor* / pathology
  • Sjogren's Syndrome* / pathology
  • Sweden / epidemiology

Substances

  • 2'-carbomethoxyphenyl 4-guanidinobenzoate